MRI-Guided Region-of-Interest Delineation Is Comparable to Manual Delineation in Dopamine Transporter SPECT Quantification in Patients: A Reproducibility Study

A particularly sensitive step in the quantification of SPECT images of the dopamine transporter (DAT) is a correct delineation of the region of interest (ROI). In this study, we primarily compared the reproducibility of the following different approaches for ROI delineation in SPECT images of the DAT: the use of manual delineation (MD) on high-count striatal slides directly on the SPECT image, ROI delineation based on individual MR images (MRD), and oversized striatal ROIs—that is, the striatal volume of interest (SVI), as described previously. We also assessed the ability of the different approaches to identify striatal pathology in patients with parkinsonism. Methods: Eight patients with highly variable reductions in cerebral DAT availability were SPECT-scanned twice with 123I-labeled N-(3-iodoprop-(2E)-enyl)-2β-carboxymethoxy-3β-(4′-methylphenyl) nortropane bolus infusion setup and once with an MRI scanner. For SPECT/MRI coregistration, we used external fiducial markers visible on both MRI and SPECT. With the MD and MRD methods, the outcome parameters for DAT availability were the binding potentials and the ratio at equilibrium of specifically bound radioligand to nondisplaceable radioligand in tissue (BPND). For the SVI method, the outcome parameter was the specific binding ratio (SBR). Results: No statistically significant difference in striatal BPND intraobserver reproducibility was seen among any of the 3 methods. The intraobserver reproducibility average ± SD for MD was 7.0% ± 4.1%; for MRD, 5.7% ± 5.4%; and for SVI, 6.7% ± 6.0%. Mean intrasubject variability, as determined from the test–retest scans, did not differ with the 3 delineation methods used. The average (±SD) intrasubject variability of striatal BPND was 11.9% ± 10.0% with MD and 14.6% ± 15.3% with MRD. With the SVI method, the intrasubject variability of striatal specific binding ratio was 10.0% ± 10.2%. BPND values obtained with the MD and MRD methods were similar (paired t test, P > 0.4). Conclusion: In patients with reduced striatal DAT binding, the reproducibility of the outcome from ROI MD is comparable to both that obtained by delineation of ROI on individual MR images, followed by coregistration to the SPECT image, and that obtained with the SVI-based approach.

[1]  Denis Guilloteau,et al.  PE2I: A Radiopharmaceutical for In vivo Exploration of the Dopamine Transporter , 2008, CNS neuroscience & therapeutics.

[2]  M Laruelle,et al.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S Y Bao,et al.  Imaging of Dopamine Transporters With Technetium‐99m TRODAT‐1 and Single Photon Emission Computed Tomography , 2000, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[4]  J. Seibyl,et al.  Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  P. Morrish How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? , 2003, Movement disorders : official journal of the Movement Disorder Society.

[6]  H. Kretschmann,et al.  Neuroanatomy and Cranial Computed Tomography , 1986 .

[7]  Masanori Ichise,et al.  Reproducibility of dopamine transporter density measured with123I-FPCIT SPECT in normal control and Parkinson’s disease patients , 2004, Annals of nuclear medicine.

[8]  Willibald Gerschlager,et al.  Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.

[9]  Caroline Prunier,et al.  Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT , 2003, NeuroImage.

[10]  Werner Poewe,et al.  Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.

[11]  W. Weber,et al.  Role of DAT‐SPECT in diagnostic work‐up of Parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.

[12]  Christine DeLorenzo,et al.  Modeling Considerations for In Vivo Quantification of the Dopamine Transporter using [11C]PE2I and Positron Emission Tomography , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  C. Svarer,et al.  Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Olaf B. Paulson,et al.  MR-based automatic delineation of volumes of interest in human brain PET images using probability maps , 2005, NeuroImage.

[15]  H. Kung,et al.  Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J B Habraken,et al.  Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  J. Seibyl,et al.  Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[18]  J. Seibyl,et al.  Do dopamine agonists or levodopa modify Parkinson's disease progression? , 2002, European journal of neurology.

[19]  S. Asenbaum,et al.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.

[20]  C. Svarer,et al.  Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  P B Hoffer,et al.  Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  L. Regeur,et al.  Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Donald Grosset,et al.  Role of dopamine transporter imaging in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.

[25]  W. Hwang,et al.  Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Willibald Gerschlager,et al.  Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study. , 2002, Movement disorders : official journal of the Movement Disorder Society.

[27]  Perry E Radau,et al.  Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Søren Holm,et al.  Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Habib Zaidi,et al.  Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use? , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  R. Haaxma Neuroanatomy and cranial computed tomography, Hans-Joachim Kretschmann, Wolfgang Weinrich. Georg Thieme Verlag, Stuttgart (1986), 168, figs and tables, DM 198.-., ISBN: 3 13 672601 4 , 1986 .

[31]  John S. Fleming,et al.  Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  W Martin,et al.  Downscatter correction and choice of collimator in 123I imaging. , 2006, Physics in medicine and biology.